Brenda L Gallie, MD, FRCPC

My work focused on the rare cancer in children, retinoblastoma, crosses many disciplines in several institutions within the University of Toronto. My basic lab defines genomic changes that drive retinoblastoma and other cancers. I direct the clinical Retinoblastoma Program and the global hub. I lead Retinoblastoma Solutions in the clinical testing and research into mutations that initiate and cause progression of retinoblastoma. Over many years, we have contributed significantly to understanding cancer in general, by revealing the basic molecular processes that go wrong, then applying this knowledge to improve healthcare.

Concerned that our science was applied to only the lucky 8% of retinoblastoma children in developed countries, I initiated an international network to put science and optimal care within reach of the 8,000 children affected per year. The network is developing clinical trials, accessible genetic testing and rapid implementation of science at the point-of-care. The global network is rapidly improving care in Eastern Africa, India and China. For example, we have discovered a new genomic basis for some retinoblastomas, and Toronto-Beijing studies have changed care strategies by revealing high mortality when over-use of chemotherapy for severe intraocular retinoblastoma delays simple curative surgery.

For a list of Dr. Gallie's publications, please visit PubMed, Scopus or ORCID.


Professor, Molecular & Medical Genetics, University of Toronto
Professor, Medical Biophysics, University of Toronto
Professor, Ophthalmology, University of Toronto